Tissue Regenix Group PLC Distribution agreement with Australian Allografts (5815A)
May 25 2023 - 1:00AM
UK Regulatory
TIDMTRX
RNS Number : 5815A
Tissue Regenix Group PLC
25 May 2023
Tissue Regenix Group plc
('Tissue Regenix', the 'Company' or the 'Group')
Multi-year distribution agreement with Australian Allografts
Tissue Regenix (AIM: TRX), the regenerative medical device
company, announces that it has signed an exclusive distribution
agreement with Australian Allografts for the distribution of the
Tissue Regenix OrthoPure (R) XT product in Australia and New
Zealand. This is subject to regulatory approval from the
Therapeutic Goods Administration ('TGA').
As part of the agreement, Australian Allografts and Tissue
Regenix are mutually committed to achieving the TGA regulatory
approval process to enable the import and distribution of the
products. The initial distribution agreement is for three years and
requires Australian Allografts to purchase a minimum unit volume
each year after achieving the TGA approval.
The OrthoPure (R) XT decellularised xenograft ligament utilises
Tissue Regenix's patented dCELL(R) technology and is the only
available, non-human biologic graft for certain anterior cruciate
ligament ('ACL') reconstruction procedures on the market. OrthoPure
(R) XT can also be used in the reconstruction of other knee
ligaments, including multi-ligament and primary procedures when an
autograft is not an option.
Kirsten Lund, EMEA Business Director for Tissue Regenix, said:
"This distribution agreement will allow physicians and patients
better access to our innovative products through the Australian
Allografts network and is another major step towards Tissue Regenix
becoming a global player in the regenerative medicine market. We
look forward to working with Australian Allografts."
Andrew Lambing, Managing Director for Australian Allografts ,
commented: "We are excited to partner with Tissue Regenix, bringing
together two organisations with a clear focus for best patient
outcome and delivering the latest technologies in tissue
development and processing for Australia and New Zealand."
For more information:
Tissue Regenix Group plc www.tissueregenix.com
Daniel Lee, Chief Executive Officer via Walbrook PR
finnCap Ltd (Nominated Adviser and Broker)
Emily Watts/Geoff Nash/George Dollemore -
Corporate Finance
Nigel Birks/Harriet Ward - ECM
Walbrook PR (Financial PR and IR) Tel: +44 (0)20 7933 8780
Alice Woodings/Lianne Applegarth TissueRegenix@walbrookpr.com
About Tissue Regenix ( www.tissueregenix.com )
Tissue Regenix is a leading medical device company in
regenerative medicine. The Company's patented decellularisation
technology ('dCELL(R)') removes DNA and other cellular material
from animal and human soft tissue, leaving an acellular tissue
scaffold not rejected by the patient's body that can be used to
repair diseased or damaged body structures. Current applications
address many crucial clinical needs in sports medicine, foot and
ankle and wound care.
In August 2017, Tissue Regenix acquired CellRight
Technologies(R). This biotech company specialises in regenerative
medicine and is dedicated to developing high-quality, innovative
tissue scaffolds to enhance healing opportunities in defects
created by trauma and disease. CellRight's human tissue products
may be used in spine, trauma, general orthopaedic, dental and
ophthalmological surgical procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGREAFSLADNDEAA
(END) Dow Jones Newswires
May 25, 2023 02:00 ET (06:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2024 to May 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2023 to May 2024